Dislocated hip hemiarthroplasties (HA) are associated with a 45% revision rate and 40% mortality rate. Implant selection for HA operations vary with no universally accepted implant choice. The WHiTE3 trial suggested older designs such as the Thompson has equitable outcomes to more modern and expensive implants such as the Exeter V40+Unitrax. Our multi-centre consecutive series of NOFs patients treated with HA assesses the impact of surgical and patient factors on dislocation risk. Medical and radiographic records for patients treated between 1stJanuary 2009 and 30thSeptember 2017 with a HA at three acute hospitals were reviewed. Implant and dislocation data were recorded. Patient demographics, comorbidities and operation details were extracted from the medical records and NHFD. Patients were excluded if there were no postoperative radiographs or when HA had been performed as a revision procedure.Introduction
Methods
